Results of 2018 Annual General Meeting

RNS Number : 1645R

Ergomed plc

12 June 2018

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

Results of 2018 Annual General Meeting

London, UK - 12 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.

Resolutions 1 to 5 were passed on a show of hands.

Details of proxy results were as follows:

Resolution number	Votes for	Votes against	Abstentions
1	21,318,347	Nil	Nil
2	21,317,894	Nil	453
3	21,317,894	Nil	453
4	19,056,035	Nil	2,262,312
5	21,317,894	Nil	453

Details of voting results for resolutions 6 and 7 (including proxies) were as follows:

Resolution number	Votes for	Votes against	Abstentions
6	30,158,064	2,351,500	520
7	25,689,064	6,820,500	520

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

ENDS

Enquiries:

Ergomed plc		Tel: [phone]
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited		Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer		Tel: [phone]
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for UK enquiries		Tel: [phone]
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Philippa Gardner
MC Services - for Continental European enquiries		Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

END

 

 

RAGEALKAFSDPEFF